Immune gene signatures in cancer

摘要

This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

主权项

1. A method of treating a subject who has a colorectal tumor, the method comprising:
obtaining cells from the colorectal tumor; determining gene expression levels of chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), CCL19, CCL21, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, and CXCL13 in the tumor cells; comparing the tumor gene expression levels to reference gene expression levels; identifying a subject who has tumor gene expression levels above the reference gene expression levels as likely to have a positive response to cyclophosphamide, and a subject who has tumor gene expression levels below the reference gene expression levels as likely to have no response or a poor response to cyclophosphamide; selecting a treatment comprising an cyclophosphamide if tumor gene expression levels are above the reference gene expression levels, or selecting a treatment not comprising cyclophosphamide if tumor gene expression levels are below the reference gene expression levels; and administering the selected treatment to the subject.